Johnson & Johnson vaccine, towards preferential use for over 60s

• Covid-19, Ema green light for the Johnson & Johnson vaccine: "Rare events, more benefits than risks"

Share

April 20, 2021

Towards a preferential use of the Johnson & Johnson Covid vaccine for people over 60 years of age.

This would be the orientation of the ministry of health and Aifa after today's pronouncement of the EMA, which recognized the link between the vaccine and some rare thrombotic events reported in the USA, as already happened for the AstraZeneca vaccine.

Also for the latter, in Italy an indication was given to preferential use for the over-60s, since rare cases of thrombosis were also reported for AstraZeneca among younger subjects.